COMMUNIQUÉS West-GlobeNewswire

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
08/12/2025
Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage program [...]
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
08/12/2025
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, [...]
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
08/12/2025
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre [...]
Zelluna ASA: New share capital registered
08/12/2025
Oslo, Norway, 8 December, 2025: Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new shares (the " [...]
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
08/12/2025
Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus GemOx 1 This Columvi combination is available off-the-shelf and could offer a potentially [...]
SAFE - Mise à disposition du Rapport Financier Semestriel 2025
08/12/2025
Mise à disposition du Rapport Financier Semestriel 2025 Fleurieux-sur-l’Arbresle - France - le 8 décembre 2025 à 14h . Safe SA (FR001400F1V2 – ALSAF), spécialiste dans la conception, la fabrication et la [...]
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
08/12/2025
Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 [...]
Soleo Health Appoints Jody Thompson as New Senior Vice President of Business Development, Rare Disease
08/12/2025
FRISCO, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today the appointment of Jody Thompson to the role of senior [...]
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
08/12/2025
CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
08/12/2025
Company Urges Shareholders to Follow ISS’ Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a [...]
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
08/12/2025
Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response [...]
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
08/12/2025
Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional [...]
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
08/12/2025
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First ex-U.S [...]
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
08/12/2025
SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary [...]
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
08/12/2025
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight loss up to 15.3% (35. [...]
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
08/12/2025
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other [...]
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
08/12/2025
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
HealthLynked Appoints Duncan McGillivray as Chief Operating Officer to Accelerate National Expansion and Nasdaq Uplisting Strategy
08/12/2025
NAPLES, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ) , the nation's leading patient-centric healthcare networking platform, today announced the appointment of Duncan McGillivray, [...]
Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society
08/12/2025
- NON-MTS & BILATERAL MTLE: First data reported from non-MTS and bilateral MTLE subjects demonstrate robust seizure reduction - LOW DOSE COHORT: 89% median reduction in disabling seizures for unilateral subjects [...]

Pages